バンコマイシンの薬剤に関する洞察と市場予測：2032年

バンコマイシンはグリコペプチド系抗菌薬で、経口投与時の全身吸収は最小限です。この薬は腸管腔内に留まり、大腸で高濃度になります。バンコマイシンの静脈内投与は腎臓から排泄されるため、CDIの治療においてこの製剤が大腸に到達することはありません。バンコマイシンは細菌の細胞壁合成を阻害し、治療濃度では静菌作用があると考えられています。この静菌作用こそが、この抗菌薬で見られる再発の原因であると考える人もいます。バンコマイシンの経口投与の主な利点は、薬物動態がより良好であることです。バンコマイシンの副作用には、腹痛、鼓腸、吐き気、頭痛、末梢浮腫などがあります。また、バンコマイシンを投与されている患者は、まれにこの治療によりレッドマン症候群を発症する可能性があることを覚えておくことが重要です。

今後数年間で、クロストリジウムディフィシル感染症の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、バンコマイシンの優位性に影響を与える可能性のある機会を模索しています。クロストリジウムディフィシル感染症に対する他の新興製品は、バンコマイシンと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるバンコマイシン市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 クロストリジウムディフィシル感染症におけるバンコマイシンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 バンコマイシン市場評価

• クロストリジウムディフィシル感染症に対するバンコマイシンの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるクロストリジウムディフィシル感染症に対するバンコマイシンの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Vancomycin, Clinical Trial Description, 2023
• Table 2: Vancomycin, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Vancomycin Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Vancomycin Market Size in the US, in USD million (2019-2032)
• Table 7: Vancomycin Market Size in Germany, in USD million (2019-2032)
• Table 8: Vancomycin Market Size in France, in USD million (2019-2032)
• Table 9: Vancomycin Market Size in Italy, in USD million (2019-2032)
• Table 10: Vancomycin Market Size in Spain, in USD million (2019-2032)
• Table 11: Vancomycin Market Size in the UK, in USD million (2019-2032)
• Table 12: Vancomycin Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Vancomycin Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Vancomycin Market Size in the United States, USD million (2019-2032)
• Figure 3: Vancomycin Market Size in Germany, USD million (2019-2032)
• Figure 4: Vancomycin Market Size in France, USD million (2019-2032)
• Figure 5: Vancomycin Market Size in Italy, USD million (2019-2032)
• Figure 6: Vancomycin Market Size in Spain, USD million (2019-2032)
• Figure 7: Vancomycin Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Vancomycin Market Size in Japan, USD million (2019-2032)

“"Vancomycin Drug Insight and Market Forecast - 2032" report provides comprehensive insights about vancomycin for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the vancomycin for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the vancomycin for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the vancomycin market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

Vancomycin is a glycopeptide antimicrobial with minimal systemic absorption when taken orally. This medication stays within the lumen of the bowel and has high concentrations in the colon. Intravenous vancomycin is excreted renally and so plays no role in the treatment of CDI as this formulation never accesses the colon. Vancomycin inhibits bacterial cell wall synthesis and, at therapeutic concentrations, this is believed to be bacteriostatic. It is this bacteriostatic effect that some believe results in the recurrences seen with this antimicrobial. The major advantage of orally administered vancomycin is its more favorable pharmacokinetics. Side effects of vancomycin include abdominal pain, flatulence, nausea, headache, and peripheral edema. It is also important to remember that patients receiving vancomycin can, rarely, develop red-man syndrome from this therapy.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the vancomycin description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on vancomycin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the vancomycin research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around vancomycin.
• The report contains forecasted sales of vancomycin for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for vancomycin in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Vancomycin Analytical Perspective by DelveInsight

In-depth Vancomycin Market Assessment

This report provides a detailed market assessment of vancomycin for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Vancomycin Clinical Assessment

The report provides the clinical trials information of vancomycin for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence vancomycin dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to vancomycin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of vancomycin in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of vancomycin from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the vancomycin in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of vancomycin?
• What is the clinical trial status of the study related to vancomycin in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the vancomycin development?
• What are the key designations that have been granted to vancomycin for clostridium difficile infection?
• What is the forecasted market scenario of vancomycin for clostridium difficile infection?
• What are the forecasted sales of vancomycin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to vancomycin for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. Vancomycin Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Vancomycin Market Assessment

• 5.1. Market Outlook of Vancomycin in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Vancomycin in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Vancomycin in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of Vancomycin in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of Vancomycin in France for Clostridium difficile infection
  • 5.3.4. Market Size of Vancomycin in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of Vancomycin in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of Vancomycin in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of Vancomycin in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options